Profil bibliographique

Kosuke Hashimoto

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

114Publications signalées

919Citations signalées

2Affiliations récentes

Institutions déclarées

Saitama International Medical Center Saitama Medical University

Domaines associés

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentImmune cells in cancer

Publications récentes

Accès ouvert 2026 preprintOpenAlex

Concurrent Chemoradiotherapy with Daily Low-Dose Carboplatin in Older Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcomes and Prognostic Significance of Systemic Inflammation Markers

Yu Miura, Hisao Imai, Satoshi Endo, Kosuke Hashimoto et autres

0 citationsPreprints.org

Accès ouvert 2025 otherOpenAlex

Figure S1,S2,S3,S4,S5,S6,S7,S8,S9 and S10 from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy

Hiroshi Kagamu, Satoshi Yamasaki, Shigehisa Kitano, Ou Yamaguchi et autres

0 citations

Accès ouvert 2025 otherOpenAlex

Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy

Hiroshi Kagamu, Satoshi Yamasaki, Shigehisa Kitano, Ou Yamaguchi et autres

0 citations

Accès ouvert 2025 supplementary-materialsOpenAlex

Supplementary materials from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy

Hiroshi Kagamu, Satoshi Yamasaki, Shigehisa Kitano, Ou Yamaguchi et autres

0 citations

Accès ouvert 2025 otherOpenAlex

Table S1, S3 and S8 from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy

Hiroshi Kagamu, Satoshi Yamasaki, Shigehisa Kitano, Ou Yamaguchi et autres

0 citations

Accès ouvert 2025 articleOpenAlex

Prognostic biomarkers for extensive-stage small cell lung cancer receiving amrubicin following failure of chemoimmunotherapy: a retrospective cohort study

Kyoichi Kaira, Hisao Imai, Kosuke Hashimoto, Ayako Shiono et autres

0 citationsTranslational Lung Cancer Research

Accès ouvert 2025 articleOpenAlex

Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutations

Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Ayako Shiono et autres

1 citationCancer Immunology Immunotherapy

Accès ouvert 2025 preprintOpenAlex

Th7R Cells: CD4⁺ T-Cell Partners That Drive Tpex-Mediated Antitumor Immunity in the Tumor Microenvironment

Hiroshi Kagamu, Shota Takei, Satoshi Yamasaki, Ou Yamaguchi et autres

0 citationsResearch Square

Accès ouvert 2025 articleOpenAlex

Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study

Yuhei Kurata, Atsuto Mouri, Hisao Imai, Satoshi Endo et autres

0 citationsMedicina

Accès ouvert 2025 articleOpenAlex

Metabolic tumor volume on 18F-FDG uptake as a negative predictor after ipilimumab plus nivolumab in advanced non-small cell lung cancer

Kosuke Hashimoto, Kyoichi Kaira, Atsuto Mouri, Ayako Shiono et autres

1 citationTranslational Lung Cancer Research

2025 articleOpenAlex

Efficacy and Safety of Amrubicin Monotherapy After Chemoradiotherapy in Patients With Relapsed Limited Disease Small-cell Lung Cancer

Akira Matsukida, Hisao Imai, Ayako Shiono, Yasuhiro Ryuno et autres

1 citationAnticancer Research

Accès ouvert 2025 articleOpenAlex

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer

Satoshi Endo, Hisao Imai, Atsuto Mouri, Kasumi Tsukamoto et autres

2 citationsJournal of Cancer Research and Clinical Oncology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.